NCT01093755View on ClinicalTrials.gov

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
InflammationBarrett's Esophagus
Interventions
DRUG

dexlansoprazole

Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months

DRUG

Omeprazole

Escalating doses of omeprazole (20-60 mg/day) for 6 months

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT01093755 - Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation? | Biotech Hunter | Biotech Hunter